Aura Biosciences (AURA) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T15:05:45.382Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:05:45.382Z.

Quote observation: 2026-10-06T15:05:09.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -136,076,000
Quote market capitalization: 642,857,350
Total debt · period ending 2026-06-30: 16,594,000
Cash · period ending 2026-06-30: 67,836,000

FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

AURA EBITDA Yield Metrics

EBITDA YIELD

N/A

AURA Competitors' EBITDA Yield

AURA

Aura Biosciences, Inc.

Current

Market Cap

$642.86M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OABI

OmniAb, Inc.

vs AURA

Market Cap

$640.05M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLYM

Climb Bio, Inc.

vs AURA

Market Cap

$637.30M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDXG

MiMedx Group, Inc.

vs AURA

Market Cap

$665.40M

EBITDA Yield

3.84%

TTM Avg

10.03%

3Y Avg

6.88%

5Y Avg

6.20%

FDMT

4D Molecular Therapeutics, Inc.

vs AURA

Market Cap

$665.48M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANGO

AngioDynamics, Inc.

vs AURA

Market Cap

$609.24M

EBITDA Yield

N/A

TTM Avg

11.92%

3Y Avg

8.30%

5Y Avg

4.40%

HELP

Helus Pharma Inc.

vs AURA

Market Cap

$671.29M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVBP

ArriVent BioPharma, Inc.

vs AURA

Market Cap

$622.01M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANNX

Annexon, Inc.

vs AURA

Market Cap

$682.40M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FLGT

Fulgent Genetics, Inc.

vs AURA

Market Cap

$601.74M

EBITDA Yield

N/A

TTM Avg

41.20%

3Y Avg

25.05%

5Y Avg

21.67%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Aura Biosciences, Inc. (AURA)	$642.86M	N/A	N/A	N/A	N/A
OmniAb, Inc. (OABI)vs ›	$640.05M	N/A	N/A	N/A	N/A
Climb Bio, Inc. (CLYM)vs ›	$637.30M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$665.40M	3.84%	10.03%	6.88%	6.20%
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$665.48M	N/A	N/A	N/A	N/A
AngioDynamics, Inc. (ANGO)vs ›	$609.24M	N/A	11.92%	8.30%	4.40%
Helus Pharma Inc. (HELP)vs ›	$671.29M	N/A	N/A	N/A	N/A
ArriVent BioPharma, Inc. (AVBP)vs ›	$622.01M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$682.40M	N/A	N/A	N/A	N/A
Fulgent Genetics, Inc. (FLGT)vs ›	$601.74M	N/A	41.20%	25.05%	21.67%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

AURA EBITDA Yield Metrics

AURA Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics